Anti-mycobacterial function of macrophages is impaired in a diet induced model of type 2 diabetes

Tuberculosis

Volumn 102, Issue , 2017, Pages 47-54

  Alim, Md Abdul ^a   Sikder, Suchandan ^a   Bridson, Tahnee L ^a   Rush, Catherine M ^a   Govan, Brenda L ^a   Ketheesan, Natkunam ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Macrophage; Murine model; Phagocytosis; Tuberculosis; Type 2 diabetes

Indexed keywords

CORD FACTOR; GAMMA INTERFERON; INTERLEUKIN 12; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOLIC ACID; TUMOR NECROSIS FACTOR; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE RESPONSE; HOST PATHOGEN INTERACTION; IN VITRO STUDY; INTERNALIZATION; LIVER; LUNG; LUNG ALVEOLUS MACROPHAGE; MALE; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM FORTUITUM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN; ANIMAL; ATYPICAL MYCOBACTERIOSIS; BACTERIAL LOAD; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; COMPLICATION; DIET; DISEASE PREDISPOSITION; EXPERIMENTAL DIABETES MELLITUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; OPPORTUNISTIC INFECTION; PATHOLOGY;

ANIMALS; BACTERIAL LOAD; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET; DISEASE SUSCEPTIBILITY; HOST-PATHOGEN INTERACTIONS; LIVER; LUNG; MACROPHAGES, ALVEOLAR; MACROPHAGES, PERITONEAL; MALE; MICE, INBRED C57BL; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; OPPORTUNISTIC INFECTIONS; PHAGOCYTOSIS; SPLEEN;

EID: 85006165428     PISSN: 14729792     EISSN: 1873281X     Source Type: Journal    
DOI: 10.1016/j.tube.2016.12.002     Document Type: Article

References (42)

1. [1] Anonymous, Global report on diabetes., 2016, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland, 1–86.
2. [2] Martinez, N., Kornfeld, H., Diabetes and immunity to tuberculosis. Eur J Immunol 44:3 (2014), 617–626.
3. [3] Bridson, T.L., Govan, B.L., Norton, R.E., Schofield, L., Ketheesan, N., The double burden: a new-age pandemic meets an ancient infection. Trans R Soc Trop Med Hyg 108:11 (2014), 676–678.
4. [4] Hodgson, K., Morris, J., Bridson, T., Govan, B., Rush, C., Ketheesan, N., Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology 144:2 (2015), 171–185.
5. [5] Bridson, T., Govan, B., Ketheesan, N., Norton, R., Overrepresentation of diabetes in soft tissue nontuberculous mycobacterial infections. Am J Trop Med Hyg 95:3 (2016), 528–530.
6. [6] Ioachimescu, O.C., Tomford, J.W., Nontuberculous mycobacterial disorders. Carey, W., (eds.) Disease management project, 2016, Cleveland Clinic—Centre for Continuing Education, Cleveland, OH, USA Available online: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/infectious disease/nontuberculous-mycobacterial-disorders/ (Accessed on 31 October 2016), 2016.
7. [7] Morris, J.L., Bridson, T.L., Alim, M.A., Rush, C.M., Rudd, D.M., Govan, B.L., et al. Development of a diet-induced murine model of diabetes featuring cardinal metabolic and pathophysiological abnormalities of type 2 diabetes. Biol Open 5:8 (2016), 1149–1162.
8. [8] Hodgson, K., Govan, B., Ketheesan, N., Morris, J., Dietary composition of carbohydrates contributes to the development of experimental type 2 diabetes. Endocrine 43:2 (2013), 447–451.
9. [9] Surwit, R.S., Kuhn, C.M., Cochrane, C., McCubbin, J.A., Feinglos, M.N., Diet-induced type II diabetes in C57BL/6J mice. Diabetes 37:9 (1988), 1163–1167.
10. [10] Cooper, A.M., Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27 (2009), 393–422.
11. [11] Parti, R.P., Srivastava, S., Gachhui, R., Srivastava, K.K., Srivastava, R., Murine infection model for Mycobacterium fortuitum. Microbes Infect 7:3 (2005), 349–355.
12. [12] Flynn, J.L., Scanga, C.A., Tanaka, K.E., Chan, J., Effects of aminoguanidine on latent murine tuberculosis. J Immunol 160:4 (1998), 1796–1803.
13. [13] Retzinger, G.S., Meredith, S.C., Takayama, K., Hunter, R.L., Kezdy, F.J., The role of surface in the biological activities of trehalose 6,6'-dimycolate. Surface properties and development of a model system. J Biol Chem 256:15 (1981), 8208–8216.
14. [14] Indrigo, J., Hunter, R.L. Jr., Actor, J.K., Cord factor trehalose 6,6'-dimycolate (TDM) mediates trafficking events during mycobacterial infection of murine macrophages. Microbiology 149:Pt 8 (2003), 2049–2059.
15. [15] Collins, A.M., Rylance, J., Wootton, D.G., Wright, A.D., Wright, A.K., Fullerton, D.G., et al. Bronchoalveolar lavage (BAL) for research; obtaining adequate sample yield. J Vis Exp, 85, 2014.
16. [16] Hodgson, K.A., Morris, J.L., Feterl, M.L., Govan, B.L., Ketheesan, N., Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes. Microbes Infect 13:14–15 (2011), 1177–1184.
17. [17] Honda, J.R., Knight, V., Chan, E.D., Pathogenesis and risk factors for nontuberculous mycobacterial lung disease. Clin Chest Med 36:1 (2015), 1–11.
18. [18] Orme, I.M., Ordway, D.J., Host response to nontuberculous mycobacterial infections of current clinical importance. Infect Immun 82:9 (2014), 3516–3522.
19. [19] Ahmad, S., Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin Dev Immunol, 2011, 2011, 814943.
20. [20] Silva, T.R., Petersen, A.L., Santos Tde, A., Almeida, T.F., Freitas, L.A., Veras, P.S., Control of Mycobacterium fortuitum and Mycobacterium intracellulare infections with respect to distinct granuloma formations in livers of BALB/c mice. Mem Inst Oswaldo Cruz 105:5 (2010), 642–648.
21. [21] Orme, I.M., Collins, F.M., Resistance of various strains of mycobacteria to killing by activated macrophages in vivo. J Immunol 131:3 (1983), 1452–1454.
22. [22] Maeda, N., Nigou, J., Herrmann, J.L., Jackson, M., Amara, A., Lagrange, P.H., et al. The cell surface receptor DC-SIGN discriminates between Mycobacterium species through selective recognition of the mannose caps on lipoarabinomannan. J Biol Chem 278:8 (2003), 5513–5516.
23. [23] Saiki, O., Negoro, S., Tsuyuguchi, I., Yamamura, Y., Depressed immunological defence mechanisms in mice with experimentally induced diabetes. Infect Immun 28:1 (1980), 127–131.
24. [24] Yamashiro, S., Kawakami, K., Uezu, K., Kinjo, T., Miyagi, K., Nakamura, K., et al. Lower expression of Th1-related cytokines and inducible nitric oxide synthase in mice with streptozotocin-induced diabetes mellitus infected with Mycobacterium tuberculosis. Clin Exp Immunol 139:1 (2005), 57–64.
25. [25] Martens, G.W., Arikan, M.C., Lee, J., Ren, F., Greiner, D., Kornfeld, H., Tuberculosis susceptibility of diabetic mice. Am J Respir Cell Mol Biol 37:5 (2007), 518–524.
26. [26] Vallerskog, T., Martens, G.W., Kornfeld, H., Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J Immunol 184:11 (2010), 6275–6282.
27. [27] Bowdish, D.M., Sakamoto, K., Kim, M.J., Kroos, M., Mukhopadhyay, S., Leifer, C.A., et al. MARCO, TLR2, and CD14 are required for macrophage cytokine responses to mycobacterial trehalose dimycolate and Mycobacterium tuberculosis. PLoS Pathog, 5(6), 2009, e1000474.
28. [28] Appelberg, R., Castro, A.G., Pedrosa, J., Silva, R.A., Orme, I.M., Minóprio, P., Role of gamma interferon and tumor necrosis factor alpha during T-cell-independent and -dependent phases of Mycobacterium avium infection. Infect Immun 62:9 (1994), 3962–3971.
29. [29] Ehlers, S., Benini, J., Kutsch, S., Endres, R., Rietschel, E.T., Pfeffer, K., Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 67:7 (1999), 3571–3579.
30. [30] Brode, S.K., Jamieson, F.B., Ng, R., Campitelli, M.A., Kwong, J.C., Paterson, J.M., et al. Increased risk of mycobacterial infections associated with anti-rheumatic medications. Thorax 70:7 (2015), 677–682.
31. [31] Ma, H., Liu, G., Ding, W., Wu, Y., Cai, L., Zhao, Y., Diabetes-induced alteration of F4/80+ macrophages: a study in mice with streptozotocin-induced diabetes for a long term. J Mol Med Berl 86:4 (2008), 391–400.
32. [32] Martinez, N., Ketheesan, N., West, K., Vallerskog, T., Kornfeld, H., Impaired recognition of mycobacterium tuberculosis by alveolar macrophages from diabetic mice. J Infect Dis 214:11 (2016), 1629–1637.
33. [33] Lachmandas, E., Vrieling, F., Wilson, L.G., Joosten, S.A., Netea, M.G., Ottenhoff, T.H., et al. The effect of hyperglycaemia on in vitro cytokine production and macrophage infection with Mycobacterium tuberculosis. PLoS One, 10(2), 2015, e0117941.
34. [34] Cebula, B.R., et al. Mycobacterium avium serovars 2 and 8 infections elicit unique activation of the host macrophage immune responses. Eur J Clin Microbiol Infect Dis 31:12 (2012), 3407–3412.
35. [35] Da Silva, T.R., De Freitas, J.R., Silva, Q.C., Figueira, C.P., Roxo, E., Leao, S.C., et al. Virulent Mycobacterium fortuitum restricts NO production by a gamma interferon-activated J774 cell line and phagosome-lysosome fusion. Infect Immun 70:10 (2002), 5628–5634.
36. [36] Sugawara, I., Mizuno, S., Higher susceptibility of type 1 diabetic rats to Mycobacterium tuberculosis infection. Tohoku J Exp Med 216:4 (2008), 363–370.
37. [37] Scanga, C.A., Mohan, V.P., Tanaka, K., Alland, D., Flynn, J.L., Chan, J., The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun 69:12 (2001), 7711–7717.
38. [38] Fulton, S.A., Cross, J.V., Toossi, Z.T., Boom, W.H., Regulation of interleukin-12 by interleukin-10, transforming growth factor-beta, tumor necrosis factor-alpha, and interferon-gamma in human monocytes infected with Mycobacterium tuberculosis H37Ra. J Infect Dis 178:4 (1998), 1105–1114.
39. [39] Sun, C., Sun, L., Ma, H., Peng, J., Zhen, Y., Duan, K., et al. The phenotype and functional alterations of macrophages in mice with hyperglycemia for long term. J Cell Physiol 227:4 (2012), 1670–1679.
40. [40] Singh, P.P., Goyal, A., Interleukin-6: a potent biomarker of mycobacterial infection. SpringerPlus 2:1 (2013), 1–8.
41. [41] Martinez, A.N., Mehra, S., Kaushal, D., Role of interleukin 6 in innate immunity to Mycobacterium tuberculosis infection. J Infect Dis 207:8 (2013), 1253–1261.
42. [42] Kipnis, A., Basaraba, R.J., Orme, I.M., Cooper, A.M., Role of chemokine ligand 2 in the protective response to early murine pulmonary tuberculosis. Immunology 109:4 (2003), 547–551.